Table 3.
Comparison of world Segi 1960 age-standardized rates between southern European countries (1).
| ASRSEGI | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spain | Portugal | Greece | Cyprus (south-west) | Croatia | France | Bulgaria | Italy | Malta | ||||||
| I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases | ||||||||||||||
| 47.3 | 44.6 | 51.9 | 58.0 | 60.3 | 45.2 | 43.4 | 58.4 | 60.7 | ||||||
| Ia. Lymphoid leukemias | ||||||||||||||
| 35.8 | 32.3 | 45.2 | 44.5 | 50.5 | 34.5 | 32.5 | 47.1 | 46.1 | ||||||
| Ib. Acute myeloid leukemias | ||||||||||||||
| 7.9 | 8.2 | 5.5 | 10.1 | 7.7 | 6.9 | 4.8 | 7.7 | 7.5 | ||||||
| Ic. Chronic myeloproliferative diseases | ||||||||||||||
| 1.1 | 1.3 | 0.5 | 0.4 | 0.8 | 1.0 | 1.0 | 1.6 | 3.8 | ||||||
| Id. Myelodysplastic syndrome | ||||||||||||||
| 1.0 | 1.5 | 0.1 | 1.3 | 0.3 | 1.6 | 0.4 | 0.7 | 2.7 | ||||||
| Ie. Unspecified and other specified leukemias | ||||||||||||||
| 1.5 | 1.2 | 0.5 | 1.6 | 1.0 | 1.2 | 4.7 | 1.2 | 0.7 | ||||||
| II. Lymphomas and reticuloendothelial neoplasms | ||||||||||||||
| 19.4 | 22.8 | 15.9 | 23.8 | 23.1 | 20.0 | 18.1 | 25.7 | 21.8 | ||||||
| IIa. Hodgkin lymphomas | ||||||||||||||
| 5.3 | 8.7 | 6.1 | 12.1 | 7.2 | 7.1 | 8.2 | 10.3 | 6.8 | ||||||
| IIb. Non-Hodgkin lymphomas (except Burkitt’s lymphoma) | ||||||||||||||
| 5.8 | 6.7 | 5.3 | 9.2 | 7.8 | 6.2 | 6.0 | 7.4 | 6.0 | ||||||
| IIc. Burkitt’s lymphoma | ||||||||||||||
| 5.4 | 4.6 | 4.5 | 1.8 | 2.9 | 4.9 | 1.7 | 4.6 | 3.9 | ||||||
| IId. Miscellaneous lymphoreticular neoplasms | ||||||||||||||
| 2.3 | 2.1 | 0.0 | 0.0 | 5.1 | 1.5 | 1.4 | 2.6 | 5.1 | ||||||
| IIe. Unspecified and other specified lymphomas | ||||||||||||||
| 0.4 | 0.7 | 0.0 | 0.8 | 0.2 | 0.2 | 0.8 | 0.8 | 0.0 | ||||||
ASRSEGI, age-standardized rate using the 1960 Segi world population.